2. Search Result
Search Result
Results for "

MOLM-16

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108696
    GNE-781
    3 Publications Verification

    		 Epigenetic Reader Domain Histone Acetyltransferase Cancer
    GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model .
    GNE-781
  • HY-153023
    PROTAC STAT3 degrader-2

    		PROTACs STAT Cancer
    PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC50 of 3.54 μM in Molm-16 Cell. PROTAC STAT3 degrader-2 has the potential for cancer research . PROTAC STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PROTAC STAT3 degrader-2
  • HY-155529
    FD1024

    		Pim Cancer
    FD1024 is PIM inhibitor (IC50s: 1.96, 38.9, 4.17 nM for PIM1, 2, 3). FD1024 can be used for research of acute myeloid leukemia. FD1024 has strong antiproliferative activity against the tested AML cell lines, with 0.16 μM, 0.12 μM, 1.05 μM, 1.39μM for EOL-1, MV-4-11, KG-1, MOLM-16 cells. FD1024 also has antitumor efficacy in mice .
    FD1024
  • HY-155066
    FD274

    		PI3K mTOR Cancer
    FD274 is a highly potent PI3K/mTOR dual inhibitor with IC50s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60 and MOLM-16). FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .
    FD274
  • HY-161494
    XYD190

    		PROTACs Epigenetic Reader Domain Cancer
    XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC50 of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .
    XYD190
  • HY-161498
    XYD198

    		PROTACs Epigenetic Reader Domain Cancer
    XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC50 of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))
    XYD198
  • HY-161495
    CBP/p300 ligand 4

    		Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC50 of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .
    CBP/p300 ligand 4
  • HY-161496
    Boc-NHCH2-Ph-Py-NH2

    		PROTAC Linkers Cancer
    Boc-NHCH2-Ph-Py-NH2 is the linker for PROTAC molecule XYD190 (HY-161494) .
    Boc-NHCH2-Ph-Py-NH2
  • HY-161497
    Thalidomide-benzylamine-Py-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-benzylamine-Py-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and the Linker Boc-NHCH2-Ph-Py-NH2 (HY-161496). Thalidomide-benzylamine-Py-NH2 is utilized for synthesis of PROTAC molecule XYD190 (HY-161494) .
    Thalidomide-benzylamine-Py-NH2
  • HY-161499
    Boc-NHCH2-Ph-pyrimidine-NH2

    		PROTAC Linkers Cancer
    Boc-NHCH2-Ph-pyrimidine-NH2 is the linker for PROTAC molecule XYD198 (HY-161498) .
    Boc-NHCH2-Ph-pyrimidine-NH2
  • HY-161500
    Thalidomide-NHCH2-Ph-pyrimidine-NH2

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-NHCH2-Ph-pyrimidine-NH2 is a conjugate of E3 ligase ligand and linker, which is consisted of a Thalidomide (HY-14658) and a Linker Boc-NHCH2-Ph-pyrimidine-NH2 (HY-161499). Thalidomide-NHCH2-Ph-pyrimidine-NH2 is utilized for synthesis of PROTAC molecule XYD198 (HY-161498) .
    Thalidomide-NHCH2-Ph-pyrimidine-NH2
  • HY-132231
    FD223

    		PI3K Apoptosis Cancer
    FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML .
    FD223

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: